Satellos Bioscience Inc.
MSLE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MSLE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MSLE
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing therapies for degenerative muscle diseases, with its lead candidate SAT-3247 targeting Duchenne muscular dystrophy and currently in Phase 2 trials.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials · 1 catalyst for Satellos Bioscience Inc..
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing therapies for degenerative muscle diseases, with its lead candidate SAT-3247 targeting Duchenne muscular dystrophy and currently in Phase 2 trials.
- Satellos reported cash available of $69.9M (Cdn $97.5M) as of May 15, 2026, providing runway through 2027 [news · 2026-05-15].
- The BASECAMP study remains on track to complete enrollment in Q3 2026, with eleven clinical trial sites currently active [news · 2026-05-15].
- The TRAILHEAD study has been initiated in the U.S. in adults aged 16-25 years [news · 2026-05-15].
- SAT-3247 received FDA Fast Track designation for Duchenne muscular dystrophy as of June 29, 2026 [news · 2026-06-29].
- New data from the SAT-3247 clinical program will be presented at ICNMD 2026 in July 2026 [news · 2026-06-25].
What works
- FDA Fast Track designation for SAT-3247 may expedite development and regulatory review for Duchenne muscular dystrophy [news · 2026-06-29].
- Cash runway through 2027 provides financial stability for ongoing clinical programs [news · 2026-05-15].
- Multiple clinical studies (BASECAMP and TRAILHEAD) are actively enrolling, indicating progress in the pipeline [news · 2026-05-15].
What to weigh
- The company reported a net loss of $24.9M for the year ended 2025-12-31, reflecting high cash burn typical of clinical-stage biotechs [latest reported financials].
- As a clinical-stage company with no approved products, Satellos is dependent on successful trial outcomes and future financing [news · 2026-05-15].
- The competitive landscape for Duchenne muscular dystrophy includes other therapies, though no direct competitor trials were identified in the provided data.
From the filings
Quoted directly from source documents.
Cash runway through 2027
“Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027”
News · May 15, 2026
BASECAMP enrollment timeline
“BASECAMP remains on track to complete enrollment in Q3 2026”
News · May 15, 2026
FDA Fast Track designation
“Satellos Gets FDA Fast Track Status For Duchenne Drug”
News · June 29, 2026
TRAILHEAD study initiation
“The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.”
News · May 15, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · sat-3247 — Phase 2 Readout: sat-3247 — Topline results from the Phase 2 study of SAT-3247 are expected, which will inform efficacy and safety for Duchenne muscular dystrophy.
Risks & what to watch (3)›
Key risks
- Clinical trial failure risk — SAT-3247 is in Phase 2; negative results could halt development and impact viability [news · 2026-05-15].
- Cash burn and dilution — Net loss of $24.9M in 2025; cash runway through 2027 may require additional financing [latest reported financials].
- Regulatory and competitive risk — Duchenne market has existing and emerging therapies; Fast Track does not guarantee approval [news · 2026-06-29].
What to watch
- Completion of BASECAMP enrollment in Q3 2026 [news · 2026-05-15].
- Presentation of SAT-3247 data at ICNMD 2026 in July 2026 [news · 2026-06-25].
- Phase 2 topline results for SAT-3247 expected by end of 2026 [upcoming catalysts].
- Activation of remaining BASECAMP trial sites in Q2 2026 [news · 2026-05-15].
Sources: Competitor trials · News · Generated August 27, 2026 · How we verify sources →
Run Satellos Bioscience Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Satellos Bioscience Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.1 months
D/E 0.15
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
26
Total value held
$27.1M
| Holder | Shares | Value |
|---|---|---|
| franklin resources inc | 938,666 | $5.3M |
| avidity partners management lp | 775,538 | $5.3M |
| sphera funds management ltd. | 489,207 | $2.8M |
| suvretta capital management, llc | 475,000 | $2.7M |
| adage capital partners gp, l.l.c. | 380,354 | $2.1M |
| saturn v capital management lp | 350,000 | $2.0M |
| millennium management llc | 298,433 | $1.7M |
| 683 capital management, llc | 230,833 | $1.3M |
| empery asset management, lp | 230,100 | $1.3M |
| adar1 capital management, llc | 222,555 | $1.3M |
Showing top 10 of 26 institutional holders of Satellos Bioscience Inc.. Open the full 13F history after sign-in.
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Jun 23, 2026)
- 57.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MSLE short interestFrequently asked questions
What is the AI investment thesis for Satellos Bioscience Inc.?
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing therapies for degenerative muscle diseases, with its lead candidate SAT-3247 targeting Duchenne muscular dystrophy and currently in Phase 2 trials.
What is Satellos Bioscience Inc.'s next catalyst?
Satellos Bioscience Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sat-3247" — expected December 31, 2026.
Who is the CEO of Satellos Bioscience Inc.?
Mr. Francis Gleeson B.B.A. M.B.A is the chief executive officer of Satellos Bioscience Inc. (MSLE).
Where is Satellos Bioscience Inc. headquartered?
Satellos Bioscience Inc. (MSLE) is headquartered in Toronto, ON, Canada.
What therapeutic areas does Satellos Bioscience Inc. focus on?
Satellos Bioscience Inc. develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.